BLASUBCUTANEOUSVIAL
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
KINERET (anakinra) by Swedish Orphan Biovitrum is interleukin 1 receptor antagonists [moa]. First approved in 2001.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KINERET (anakinra) is a recombinant interleukin-1 receptor antagonist administered subcutaneously as a vial injection. It blocks IL-1 signaling to reduce inflammation in conditions like rheumatoid arthritis and other inflammatory disorders. The drug has been approved since 2001 and represents a foundational biologic in the IL-1 inhibition space.
$28MPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Part D spending (~$28M, 4,819 claims in 2023), indicating a mature, niche market with limited growth trajectory and smaller commercial teams.
Mechanism of Action
Interleukin 1 Receptor Antagonists
Pharmacologic Class:
Interleukin-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
Started Sep 2025
30 enrolled
Cryopyrin-Associated Periodic SyndromesAmyloidosis
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
Started Sep 2025
3 enrolled
Familial Mediterranean Fever (FMF )
A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment
Started Oct 2023
84 enrolled
Kawasaki Disease
A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF
Started Dec 2022
52 enrolled
Cystic Fibrosis, 10011762
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Started Aug 2022
15 enrolled
Still's Disease, Juvenile OnsetStill's Disease, Adult-Onset
Worked on KINERET at Swedish Orphan Biovitrum? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.